SCHEMBL392473

SCHEMBL392473

Fc1cccc(Nc2cccc(F)c2)c1

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RAPGEF4 Q8WZA2 1/20 0.61
MEN1 O00255 5/20 0.55
KMT2A Q03164 5/20 0.55
ALDH1A1 P00352 2/20 0.55
AR P10275 1/20 0.55
MAPT P10636 1/20 0.55
RAB9A P51151 4/20 0.50
NPC1 O15118 3/20 0.50
ABCG2 Q9UNQ0 2/20 0.50
EGFR P00533 2/20 0.50
IDO1 P14902 1/20 0.50
FADS1 O60427 1/20 0.50
CA12 O43570 1/20 0.48
MMP2 P08253 1/20 0.48
CA9 Q16790 1/20 0.48
CA14 Q9ULX7 1/20 0.48
TSHR P16473 1/20 0.48
DEPTOR Q8TB45 1/20 0.48
HPGD P15428 1/20 0.48
TAAR1 Q96RJ0 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30675253 1.00 RAPGEF4 (0.61) RAPGEF4MEN1KMT2AALDH1A1AR
SCHEMBL1118619 0.93 MEN1 (0.68) RAPGEF4MEN1KMT2AALDH1A1AR
SCHEMBL31002670 0.93 MEN1 (0.68) RAPGEF4MEN1KMT2AALDH1A1AR
SCHEMBL23765069 0.91 RAPGEF4 (0.53) RAPGEF4MEN1KMT2AALDH1A1AR
SCHEMBL22923287 0.89 RAPGEF4 (0.52) RAPGEF4MEN1KMT2AALDH1A1AR
SCHEMBL19656471 0.87 NPSR1 (0.67) RAPGEF4ALDH1A1MAPTRAB9ANPC1
SCHEMBL24004080 0.87 KDM4E (0.67) RAPGEF4MEN1KMT2AALDH1A1MAPT
SCHEMBL15152341 0.85 CYP3A4 (0.53) RAPGEF4MEN1KMT2AALDH1A1AR
SCHEMBL11896131 0.85 MEN1 (0.50) RAPGEF4MEN1KMT2AALDH1A1AR
SCHEMBL18646957 0.85 ABCG2 (0.54) RAPGEF4MEN1KMT2AALDH1A1AR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 116 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12577373-B2 Carbodiimide composition, curing agent composition, coating composition and resin cured product ASAHI KASEI KABUSHIKI KAISHA (JP) 2026-03-17 US disclosed
US-20230389411-A1 ORGANOMETALLIC COMPOUND, LIGHT-EMITTING DEVICE INCLUDING THE SAME, AND ELECTRONIC APPARATUS INCLUDING THE LIGHT-EMITTING DEVICE SAMSUNG DISPLAY CO., LTD. (KR) 2023-11-30 US disclosed
US-20230389411-A1 ORGANOMETALLIC COMPOUND, LIGHT-EMITTING DEVICE INCLUDING THE SAME, AND ELECTRONIC APPARATUS INCLUDING THE LIGHT-EMITTING DEVICE SAMSUNG DISPLAY CO., LTD. (KR) 2023-11-30 US disclosed
US-20230389411-A1 ORGANOMETALLIC COMPOUND, LIGHT-EMITTING DEVICE INCLUDING THE SAME, AND ELECTRONIC APPARATUS INCLUDING THE LIGHT-EMITTING DEVICE SAMSUNG DISPLAY CO., LTD. (KR) 2023-11-30 US disclosed
CN-117135987-A Organometallic compound, light-emitting device including the same, electronic device, and electronic device 三星显示有限公司 2023-11-28 CN disclosed
US-20230373919-A1 AT2R ANTAGONISTS AND USES THEREOF ELI LILLY AND COMPANY 2023-11-23 US disclosed
US-20230373919-A1 AT2R ANTAGONISTS AND USES THEREOF ELI LILLY AND COMPANY 2023-11-23 US disclosed
WO-2023224853-A1 AT2R ANTAGONISTS AND USES THEREOF ELI LILLY AND COMPANY (US) 2023-11-23 WO disclosed
US-20230373919-A1 AT2R ANTAGONISTS AND USES THEREOF ELI LILLY AND COMPANY 2023-11-23 US disclosed
US-20230135772-A1 CARBODIIMIDE COMPOSITION, CURING AGENT COMPOSITION, COATING COMPOSITION AND RESIN CURED PRODUCT ASAHI KASEI KABUSHIKI KAISHA (JP) 2023-05-04 US disclosed
US-20020143124-A1 Homogeneous type solid catalyst component or homogeneous type solid catalyst, process for production thereof and process for producing addition polymer with the same SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2002-10-03 US disclosed
EP-1153938-A1 CATALYST FOR STEREOREGULAR POLYMERIZATION OF ALPHA-OLEFIN AND PROCESS FOR PRODUCING STEREOREGULAR ALPHA-OLEFIN POLYMER SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2001-11-14 EP disclosed
US-20010020075-A1 Catalyst component for addition polymerization, catalyst for addition polymerization, and process for producing addition polymer SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2001-09-06 US disclosed
US-6284699-B1 COORDINATION POLYMERIZATION CATALYSTS SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2001-09-04 US disclosed
EP-1114832-A1 Modified particles, catalyst for olefin polymerization using the same, and process of producing olefin polymer SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2001-07-11 EP disclosed
US-20010007007-A1 Modified particles, catalyst for olefin polymerization using the same, and process of producing olefin polymer SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2001-07-05 US disclosed
EP-1113026-A2 Catalyst component for addition polymerization, catalyst for addition polymerization, and process for producing addition polymer SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2001-07-04 EP disclosed
US-6235730-B1 ANTICHOLESTEROL AGENT, ANTILIPEMIC AGENT JAPAN TOBACCO, INC. (JP) 2001-05-22 US disclosed
EP-0970954-A1 3-PIPERIDYL-4-OXOQUINAZOLINE DERIVATIVES AND MEDICINCAL COMPOSITIONS CONTAINING THE SAME JAPAN TOBACCO INC. (JP) 2000-01-12 EP disclosed
EP-0949273-A1 MODIFIED PARTICLES, CARRIER PREPARED THEREFROM, OLEFIN POLYMERIZATION CATALYST COMPONENT PREPARED THEREFROM, OLEFIN POLYMERIZATION CATALYST PREPARED THEREFROM, AND PROCESS FOR PREPARING OLEFIN POLYMER Sumitomo Chemical Company, Limited (JP) 1999-10-13 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12577373-B2 Carbodiimide composition, curing agent composition, coating composition and resin cured product CD38, PARP9, MCCC2 RAPGEF4 2821/4885MEN1 3653/4885KMT2A 182/4885
US-20230389411-A1 ORGANOMETALLIC COMPOUND, LIGHT-EMITTING DEVICE INCLUDING THE SAME, AND ELECTRONIC APPARATUS INCLUDING THE LIGHT-EMITTING DEVICE CRY1, LAGE3, NFE2L2 RAPGEF4 4019/4885MEN1 203/4885KMT2A 177/4885
US-20230373919-A1 AT2R ANTAGONISTS AND USES THEREOF AGTR2, AGTR1, AVPR2 RAPGEF4 690/4885MEN1 3920/4885KMT2A 1826/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.